logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Hengrui Pharmaceuticals (01276.HK) spent RMB 14.5036 million to repurchase 335,000 A shares on September 17.

date
17/09/2026
Zhitong Finance APP news, Hengrui Pharmaceuticals (01276.HK) announced that on September 17, 2026, it spent RMB 14.5036 million to repurchase 335,000 A shares.
Latest
4 m ago
Kaiwang Technology (301182.SZ): Controlling shareholder, actual controller, and others intend to transfer 5.6% of the company's shares by agreement.
7 m ago
Goldman Sachs is cautious on long-term bonds, saying volatility may increase further.
8 m ago
Huatai Securities (06886.HK) issues RMB1 billion corporate bonds
9 m ago
Xiangxin Technology (002965.SZ) terminates the acquisition of equity in Suzhou Ku'erxin Technology Co., Ltd.
10 m ago
Huatai Securities (06886): "25 Huatai C3" will pay interest on September 22.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.